Polymyxin B is widely used antibiotic in the clinic for resistant Gram-negative infections. In addition, polymyxin B-immobilized hemoperfusion cartridge has been used for endotoxin removal therapy in patients with septic shock. The aim of this study was to investigate the anti-fibrotic and anti-cellular hypertrophic effects of polymyxin B, and further to explore its possible mechanism. Polymyxin B (3, 10 µM) significantly inhibited stress fiber formation induced by angiotensin II (Ang II) in rat heart-derived H9c2 cells. Furthermore, polymyxin B (1 -10 µM) showed a potent inhibitory effect on Ang II-induced cellular hypertrophy in H9c2 cells. Under the mechanism study, the inhibitory activities of polymyxin B against kinases involved in cellular hypertrophy such as AKT1, CAMK, GRK5, GSK3β, MLCK, PKC, PKD2, AMPK, ROCK2, p70S6K, SGK1were evaluated. Polymyxin B possesses a potent G protein related kinase 5 (GKR5) inhibitory activity with IC50 value of 1.1 μM, and has an ATP non-competitive inhibitory mode. Taken together, these results indicate that polymyxin B alleviates Ang II-induced stress fiber formation and cellular hypertrophy, and propose that one mechanism underlying these effects involves inhibition of the GRK5 pathway.
Introduction
Physiological and pathological adaptations of cell are responses to stress that allow cells to modulate their structure and lead to escape injury. Stress fiber formation as well as cellular hypertrophy belongs to the adaptive cell response to various stimuli. However, inappropriate regulation of stress fiber formation and hypertrophic cell growth is directly involved in numerous pathological situations, including cardiovascular disease and cancer [1] [2] . In particular, cardiomyocyte hypertrophy through subsequent alterations in actin dynamics was commonly observed in heart failure including cardiac remodeling after myocardial infarction [3] [4] . Thus, the suppression of stress fiber formation and cellular hypertrophy are considered a promising pharmacological strategy for cardiovascular diseases, and a number of inhibitors have been developed accordingly [5] [6] .
Polymyxin B is a cyclic polypeptide antibiotic produced by the soil bacterium Paenibacillus polymixa [7] . It has re-emerged in clinical practice due to increasing prevalence and incidence of nosocomial infections caused by multidrug-resistance Gram-negative infections [8] . Polymyxin B can alter bacterial outer-membrane permeability and lead to disruption of membrane integrity. In addition to its antibiotic function, polymyxin B is widely applied in a medical device to remove circulating endotoxin by adsorption such as direct hemoperfusion cartridge for prevention of septic shock after various surgeries [9] [10] . Other biological effects of polymyxin B so far include induction of apoptosis [11] , modulation of ATP-sensitive potassium channels [12] , and inhibition of sarcoplasmic reticulum Ca 2+ -ATPase [13] , superoxide anion release [14] and insulin secretion [15] . To date, however, there is little information about the pharmacological actions of polymyxin B related to cardiovascular diseases, especially in conditions such as cardiac fibrosis and hypertrophy. Therefore, in the present study, we investigate the anti-fibrotic as well as anti-hypertrophic effects of polymyxin B in H9c2 cells and further explore the possible mechanism underlying these effects of polymyxin B. yl]-6-methyloctanamide, and staurosproine were purchased from Sigma-Aldrich (St. Louis, MO, USA). Human recombinant G protein related kinase 5 (GRK5) was purchased from Invitrogen (Invitrogen, Carlsbad, CA, USA). The fluorescent peptide substrate (ULightHiston H3 derived peptide) and time-resolved fluorescence resonance energy transfer (TR-FRET) Screening Kit were obtained from PerkinElmer (Waltham, MA, USA). 384-Well white flat-bottom plates were purchased from Corning Life Sciences (Lowell, MA, USA). Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum, and antibiotics were purchased from GIBCO BRL (Grand Island, NY, USA).
Materials and Methods

Materials
Polymyxin B sulfate, [N-[4-amino-1-[[1-[[4-amino-1-oxo-1-[[6,9,18-tris(2-aminoethyl)-15-benzyl-3-(1-hydroxy- ethyl)-12-(2-methylpropyl)-2,
Cell Culture
Rat heart-derived H9c2 cells were purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA) and maintained at 1 × 10 6 cells/ml in DMEM supplemented with 10% fetal bovine serum, penicillin G (100 IU/ml), streptomycin (100 μg/ml), and L-glutamine (2 mM) at 37˚C humidified atmosphere containing 5% CO 2 and 95% ambient air. Cells were then starved in serum free media for 3 h and stimulated with 0.3 µM Ang II in the presence or absence of polymyxin B (1 -30 μM) at the indicated times. Stock solutions of polymyxin B were prepared in dimethyl sulfoxide, and the maximum concentration of dimethyl sulfoxide in experimental media was 0.1%. Cells were cultured (37˚C, 5% CO 2 ) in a 16-well chamber slide (for immunofluorescent staining) or in 6-well plates (for cellular hypertrophy). Cells were used at the following passage numbers: H9c2 cells (P3-15).
Immunofluorescent Staining for F-Actin Stress Fiber Formation
H9c2 cells were plated on a chamber slide (Thermo Fisher Scientific Inc., Rochester, NY, USA) at 1 × 10 5 cells/ml. After preincubation with or without polymyxin B (1 -30 μM) for 1 h, cells were treated with Ang II (0.3 µM) for 2 h and fixed with 4% paraformaldehyde for 20 min. Fixed cells were incubated with 0.5% Triton X-100 for 5 min at −20˚C and blocked with 1% bovine serum albumin for 30 min. Cells were then probed with Alexa fluor 586 phalloidin (Invitrogen, Carlsbad, CA, USA, diluted 1:1000) for 30 min at room temperature in the dark, washed with phosphate-buffered saline solution three times, and stained with Hoechst 33342 dye for 2 min. Fluorescent images were obtained under a fluorescence microscope at 400× magnification (Nikon, Tokyo, Japan). Actin stress fiber formation was visualized using an Alexa fluor 586 phalloidin. The same fields were counter stained with Hoechst 33342 dye for the location of the nuclei. For image analysis, at least 40 cells per group were collected and determined red intensity using Image-Pro PLUS software (Media Cybernetics, Silver Spring, MD, USA). The data shown represent image analysis from 6 independent images per group.
Measurement of Cellular Hypertrophy
Cellular hypertrophy was measured from H9c2 cells treated with Ang II (0.3 µM) for 4 consecutive days. Cells were seeded at a density of 3 × 10 4 cells per 35-mm dish of 6-well plates and cultured for 24 h in DMEM containing 10% fetal bovine serum. After washing with serum-free medium (DMEM without serum), cells were treated with polymyxin B (1 -30 μM) under serum-free conditions for 24 h. Cells were then treated with potential hypertrophic agonists, Ang II (0.3 μM) in quiescence medium (DMEM with 0.5% fetal bovine serum) with or without a fresh supply of polymyxin B. Following this, cells were incubated for another 4 days at 37˚C in a humidified atmosphere containing 5% CO 2 to induce hypertrophic responses. After inducing cellular hypertrophy, adherent cells were fixed with 1% glutaraldehyde (Sigma-Aldrich) in phosphate buffered saline for 30 min and stained with 0.1% Crystal violet (Sigma-Aldrich) for 10 min. Random photographs were taken from each sample using a digital camera attached to an inverted microscope (Nikon) for analysis. At least 140 individual cells per each group were measured to determine the cell size using Image-Pro PLUS software (Media Cybernetics, Silver Spring, MD, USA). The data shown represent image analysis from 12 -14 independent images per group.
Inhibitory Activities of Polymyxin B against Kinases Involved in Cellular Hypertrophy
Under the mechanism study, the inhibitory activities of polymyxin B at the concentration of 10 μM were determined by panel screen services in EurofinsPanlabs (Test No.: AB23230; Taipei, Taiwan) using radioactive kinase assays against 10 distinct kinases involved in cellular hypertrophy such as AKT1, calcium/calmodulin-dependent protein kinase (CAMK), glycogen synthase kinase 3β (GSK3β), mysin light-chain kinase (MLCK), protein kinase C (PKC), protein kinase D2 (PKD2), AMP-activated protein kinase (AMPK), rho-associated protein kinase 2 (ROCK2), phosphoprotein 70 ribosomal protein S6 kinase (p70S6K), serum/glucocorticoid-regulated kinase 1 (SGK1).
Time-Resolved Fluorescence Resonance Energy Transfer Assay for GRK5
The inhibitory activity of polymyxin B against GRK5 was measured using LANCE ® -TR-FRET (time-resolved fluorescence resonance energy transfer; PerkinElmer, Waltham, MA, USA). In order to assume the similar sensitivity compare to the other kinase assays, the ATP concentration (10 µM) was adjusted to equal K m and the concentration of GRK5 (0.5 µg/ml) was used at an EC 50 value. ULight-Histon H3 derived peptide (PerkinElmer; 80 nM) was used as a substrate for GRK5. The kinase reaction buffer contained 50 mM HEPES (pH 7.5), 10 mMMgCl 2 , 1 mM EGTA, 2 mM DTT, 0.01% Tween 20. The total reaction volume was 10 μl and test compounds were preincubated with enzyme for 10 min before adding peptide substrate and ATP. Kinase reactions were conducted for 1 h at room temperature in standard 384-well plates (Corning Life Sciences, Lowell, MA, USA) and then 10 μl of detection mixture including 10 mM EDTA and 1 μM europium-tagged antibody (PerkinElmer) was added to reaction plates 1 h before reading. Following the addition of all reagents for reaction, the TR-FRET signal was detected using an EnVision multi-label reader (PerkinElmer) with compatible setup: excitation at 340 nm, emission at 615 nm and 665 nm with a 100 μs delay time.
Statistical Analysis
All values are expressed as means ± SDs. Data were analyzed by one-way analysis of variance (ANOVA), followed by Dunnett's test for multiple comparisons (Sigma Stat, Jandel Co., San Rafael, CA, USA). Concentration-response curves were analyzed by nonlinear regression using PRISM version 5.0 (GraphPad Software Inc., La Jolla, CA, USA), and the IC 50 value of polymyxin B (the concentration required to reduce the TR-FRET count to 50% of the positive control) was calculated. In all comparisons, statistical significance was accepted for p values of <0.05.
Results
Effects of Polymyxin B on Actin Stress Fiber Formation
To evaluate the cellular effects of polymyxin B, actin stress fiber formation assay was performed. As shown in Figure 1 , treatment with Ang II (0.3 µM) alone (Control (+)) for 2 h caused an increase of actin stress fiber formation by 86.4%. Increased number of stress fibers in Ang II-stimulated H9c2 cells was significantly decreased by pretreatment with polymyxin B (p < 0.05 at 3, 10 µM).
Effects of Polymyxin B on Cellular Hypertrophy
In H9c2 cells treated with Ang II (0.3 µM) alone (Control (+)) for 4 consecutive days, cell size was significantly increased by approximately 1.51 ± 0.17 times (Figure 2) . The Ang II-induced cellular hypertrophy was significantly inhibited by pretreatment with polymyxin B (p < 0.05 at 1 -10 µM) in a concentration-dependent manner.
Inhibitory Effects of Polymyxin B on Kinases Involved in Cellular Hypertrophy
Under the mechanism study, the inhibitory activities of polymyxin B at the concentration of 10 μM were determined for kinases (AKT1, CAMK, GRK5, GSK3β, MLCK, PKC, PKD2, AMPK, ROCK2, p70S6K, SGK1) which involved with cellular hypertrophy. As shown in Table 1 , polymyxin B showed potent inhibitory effects on the GRK5, with mild inhibitory effects on the PKD2, and no off-target inhibition with other kinases.
Inhibitory Effects of Polymyxin B on GRK5
The inhibitory activity of polymyxin B against GRK5 were measured using a kinase assay based on LANCE ® -TR-FRET, which involves specific interactions between proprietary europium-tagged antibody and ULight covalent phosphorylated moieties. Phosphosubstrate-europium-tagged antibody binding events can be directly quantified and expressed as TR-FRET counts, which reflect the amount of GRK5-induced phosphorylation of a The inhibitory activities of polymyxin B at the concentration of 10 μM were determined by panel screen services in EurofinsPanlabs (Test No.: AB23230; Taipei, Taiwan) using radioactive kinase assays. The results were expressed as a percentage inhibition relative to the control reaction without an inhibitor. Results with more than 50% of inhibition are bold typeface.
substrates. The assay conditions of GRK5-LANCE-TR-FRET assays were verified using staurosporine as a reference compound (IC 50 values: 43.5 nM), which agreed with the IC 50 values obtained from Invitrogen group through Lanta screening (90 nM). As shown in Figure 3(a) , polymyxin B inhibited the GRK5-induced TR-FRET counts in a concentration-dependent manner, and provided IC 50 value of 1.1 µM.
In the inhibition mode studies, double reciprocal plots of 1/v versus 1/[ATP] were performed using various concentrations of ATP (5 -80 µM), GRK5 (0.5 µg/ml), and ULight-Histon H3 substrate (80 nM) in the presence or absence of polymyxin B. The initial rate v was defined as rate of phospho-substrate transfer (nM/min). As shown in Figure 3(b) , the addition of polymyxin B increased the apparent the V max value for ATP of GRK5 in a concentration dependent manner without any change in the K m values. These results indicate that polymyxin B behavesas an ATP non-competitive inhibitor of GRK5.
Discussion
Polymyxin B is a cyclic polypeptide antibiotic that clinically used in the treatment of multidrug-resistant pathogens and medical device to remove circulating endotoxin by adsorption. In addition to its antimicrobial function and endotoxin-neutralizing activity, many indirect or direct biological activities of polymyxin B were reported such as protective effects against hepatic ischemia/reperfusion injury in rat with obstructive jaundice [16] , cardioprotective effects on rabbit heart with ischemic insults by modulation of ATP-sensitive potassium channels [17] , and suppression of endotoxin-induced insulin hypersecretion in pancreatic islets [18] .
In the present study, we found that polymyxin B markedly inhibited Ang II-induced actin stress fiber formation in rat heart-derived H9c2 cells. Furthermore, in the cellular hypertrophy study, Ang II-induced enlargement of cell size was significantly suppressed by polymyxin B in a concentration-dependent manner. Indeed, pathological stress fiber formation stimulates hypertrophy of myocardial cells, and this process is tightly regulated by intracellular signaling pathways connected to several protein kinases [19] . Thus, we hypothesized that the anti-fibrotic and anti-cellular hypertrophic effect of polymyxin B may be due to blocking the protein kinase dependent signaling pathway involved in cardiac hypertrophy. Under the mechanism study, the inhibitory activities of polymyxin B against kinases involved in cellular hypertrophy such as AKT1, CAMK, GRK5, GSK3β, MLCK, PKC, PKD2, AMPK, ROCK2, p70S6K, SGK1 were evaluated. Among them, polymyxin B showed potent inhibitory effects on the GRK5, with mild inhibitory effects on the related kinase PKD2, and no off-target inhibition with other kinases. It is well established that phosphorylation of class II HDAC5 (histone deacetylase 5) by regulation of PKD is an important event in the transcriptional regulation of cardiac gene reprogramming that results in the hypertrophic growth response [20] . It is also well known that GRK5 has particular relevance to the development of cardiac hypertrophy and heart failure [21] . In cultured vascular smooth muscle cells and rat aorta, Ang II-induced GRK5 up-regulation is considered as a molecular mechanism for long-term regulation [22] . GRK5 contains a phosphatidylinositol 4,5-bisphosphate binding domain, which contributes to constitutive plasma membrane localization of GRK5 by interaction with phospholipids [23] . Moreover, GRK5 has a functional nuclear localization sequence and can be found in the nucleus of cells. Recently, GRK5 is newly discovered as a nuclear HDAC kinase that plays a key role in maladaptive cardiac hypertrophy [24] . Therefore, it has been postulated that the inhibition of GRK5 can result in suppression of cardiac hypertrophy. To validate inhibitory effect of polymyxin B on GRK5, IC 50 value and inhibitory mode of polymyxin B were measured in LANCE ® -TR-FRET assay, which revealed that polymyxin B possesses a potent ability to inhibit GRK5 with IC 50 values of 1.1 μM and behaves as an ATP non-competitive inhibitor. This assay was validated with staurosporine, a non-specific kinase inhibitorbecause specific GRK5 inhibitors reported in public have been unknown until now. These results suggest that polymyxin B potently inhibits GRK5 and that by so doing it modulates actin stress fiber formation and cellular hypertrophy.
Conclusion
In conclusion, our results show for the first time that polymyxin B suppresses the stress fiber formation and cellular hypertrophy in Ang II-stimulated H9c2 cells. In addition, these anti-fibrotic and anti-cellular hypertrophic effects of polymyxin B might be, at least in part, due to the inhibition of GRK5 with ATP non-competitive manner. Further studies are necessary to elucidate the molecular entities directly responsible and other effects of polymyxin B on Ang II-induced proliferation or other growth signaling.
